工程菌BL21-PET21a(+)-phy A表达植酸酶的研究

对来源于Aspergillusniger的植酸酶基因phyA进行了改造 ,去除了内含子和信号肽编码序列后重组到表达载体PET2 1a( + )上 ,导入大肠杆菌BL2 1 (DE3)中 ,构建工程菌株BL2 1 PET2 1a( + ) phyA。植酸酶基因在工程菌株中得到了高效表达。表达产物主要以包涵体形式存在 ,表达量达到菌体蛋白的 30 %以上。改进了包涵体复性技术 ,包涵体蛋白经复性、纯化后 ,生物活性达到 1 5 0 0U mg ,并且复性蛋白具有较好的热稳定性 ,经过 75～ 95℃、30min的热处理后 ,仍然保持了生物活性 ,同时有明显的热激活现象。热激活后最高生物活性达到 5 0 0 0U mg。这一发现对于植酸酶的应用研究具有一定的意义。     

人组织性纤溶酶原激活物衍生物在大肠杆菌硫氧化还原蛋白融合表达系统中的表达

目的:克隆含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA序列(tPA355),将其在大肠杆菌融合蛋白表达系统中表达,并在体外复性使其具有激活纤溶酶原的生物活性。方法:采用RT-PCR技术从人黑色素瘤细胞Bowes中克隆出tPA355cDNA,然后在pET32a(+)BL21(DE3)大肠杆菌表达系统中表达,将表达出的融合蛋白Trx-tPA355(Thioredoxin,Trx)包涵体在体外进行变性、复性和纯化以使其具有激活纤溶酶原的生物活性。结果:测序结果表明本研究克隆的编码tPA中355个氨基酸密码子的cDNA序列与美国专利(公开号:5,587,159)中对应的序列完全一致,将其在pET32a(+)/BL21(DE3)大肠杆菌表达系统中表达可获得稳定表达的融合蛋白Trx-tPA355包涵体,该包涵体占菌体总蛋白的30%左右,此融合蛋白经变性、复性后具有激活纤溶酶原的生物活性。结论:含tPA中355个氨基酸密码子(1-3和176-527氨基酸)的cDNA在大肠杆菌Trx融合蛋白表达系统中可获得稳定表达,表达的融合蛋白产物在体外经变性、复性后具有激活纤溶酶原的生物活性。     

重组人表皮生长因子包涵体的表达、纯化及复性

目的:通过优化人表皮生长因子(hEGF)基因序列,利用大肠杆菌大量表达重组hEGF(rhEGF)包涵体,经过包涵体纯化复性获得高活性的rhEGF。方法:采用全基因合成优化后的序列,克隆至pET-30a表达载体中,转化大肠杆菌BL21(DE3),经IPTG诱导表达,将rhEGF包涵体用尿素溶解后过Ni柱纯化并稀释复性,根据药典对得到的rhEGF进行纯度及活性测定。结果:构建了rhEGF的表达载体pET-30a-rhEGF,表达出的蛋白主要存在于包涵体中,相对分子质量为6.5×10~3,包涵体经过纯化复性后获得的rhEGF纯度可达92.8%,生物活性约4.94×10~7IU/mg。结论:得到了具有较高活性的rhEGF。     

病原诱导的小麦ERF转录因子TaERF1b的原核表达及纯化

为了得到纯化的TaERFlb活性蛋白,将TaERFlb基因含有AP2／ERF结构域的片段插入原核表达载体pGEX-4T-1的多克隆位点中,构建GST-TaERFlb融合蛋白表达载体,并转化到犬肠杆菌BL21（DE3）中。0．1mmol／L1PTG即能诱导融合蛋白表达,37℃诱导4h或30℃诱导8h,融合蛋白均以包涵体的形式表达,16℃诱导12h,融合蛋白不表达。包涵体经溶解及稀释复性后,过GST亲和层析柱,获得纯化的融合蛋白,考马斯亮蓝法测得纯化蛋白的浓度约为0．5ug／ul,凝胶阻滞实验表明包涵体复性成功．所得蛋白具有生物活性：     

来源于青霉菌聚半乳糖醛酸酶的筛选及其在大肠杆菌中的异源表达

聚半乳糖醛酸酶属于果胶水解酶类,在食品、饲料、纺织和造纸等工业生产中应用广泛。本研究筛选获得一株能分解果胶的青霉菌Penicillium sp. FJ2,使用简并引物PCR和TAIL-PCR方法从该菌中克隆得到一个聚半乳糖醛酸酶基因pgp1。pgp1基因全长1 225 bp,包含2个内含子,其cDNA全长1 104 bp,编码367个氨基酸和一个终止密码子。将pgp1基因连接pET-30a(+)载体并转化大肠杆菌BL21(DE3),重组蛋白以包涵体形式获得表达。通过尿素溶解和梯度稀释方法对重组蛋白PGP1进行了重折叠复性试验,复性后的PGP1聚半乳糖醛酸酶活力达到12.9 U/mL,比活力为583 U/mg。     

重组人胰激肽原酶复性工艺的研究

目的:研究重组人胰激肽原酶包涵体变性及复性的工艺。方法:对本实验室构建的重组人胰激肽原酶大肠杆菌进行IPTG诱导表达表达成功后,菌体经超声破碎释放包涵体,包涵体经洗涤、变性、稀释和尿素梯度凝胶过滤色谱这两种方法复性后(Sephadex-G75),通过测定酶活检验复性效果。结果:①重组人胰激肽原酶工程菌经过IPTG诱导后能够表达目的蛋白,目的蛋白以包涵体形式存在,将细胞破碎后,包涵体经过3次洗涤,纯度达到71.93%;②变性包涵体经24小时稀释复性后,蛋白浓度达到72.61μg/m L,酶的比活达到13.84 U/mg;③变性包涵体经过2个小时的尿素梯度凝胶过滤复性后,蛋白浓度可达到830.07μg/mL,酶的比活达到48.61 U/mg。结论:两种复性方法均可以使包涵体达到一定的浓度和比活,比较发现尿素梯度凝胶过滤色谱具有复性时间短和比活力高等优点,可作为重组人胰激肽原酶复性的一种有效的手段。     

包涵体复性研究进展(英文)

用基因工程技术在大肠杆菌高水平表达重组蛋白时,通常形成无生物活性的包涵体。包涵体在体外经分离、溶解与重折叠后可实现复性,表现为具有生物活性的蛋白。总结了包涵体的相关复性技术,重点介绍重折叠的最新进展情况 。     

人源溶菌酶在大肠杆菌中的表达与复性研究

人源溶菌酶(Human lysozyme,HLZ)是一种糖苷水解酶,具有抗菌消炎的作用,其作为抗生素的替代品,已经被广泛应用于食品业、畜牧业和医疗等领域。如何获得高产量、高活性、高纯度的人源溶菌酶一直是亟待解决的技术问题。优化人源溶菌酶编码基因密码子,提高其在大肠杆菌中的适应度和表达量;将优化的基因克隆至大肠杆菌表达质粒pET21a,并将其在大肠杆菌表达菌株BL21(DE3)中诱导表达;利用8 mol/L尿素溶液对包涵体进行溶解变性后,探究一步透析、梯度透析和梯度稀释3种复性方式以及复性液中谷胱甘肽氧化还原对(GSSG/GSH)、精氨酸、甘油等复性物的浓度对重组人源溶菌酶复性的效果,获得最佳的复性方案。研究结果表明:37℃诱导温度下,利用0.5 mmol/L IPTG成功诱导了分子量约为14.7 kD的重组人源溶菌酶的表达,包涵体表达量约为380 mg/L(湿重)。包涵体经一步透析、梯度透析和梯度稀释3种复性方式复性后,测得比活力值分别为147 U/mg、335 U/mg、176 U/mg,表明最佳复性方法为梯度透析复性法。进一步探索了复性液中GSSG/GSH比值、精氨酸浓度、甘油浓度对人源溶菌酶复性效果的影响,表明当复性液中同时添加浓度比为1∶2的GSSG/GSH、4 mmol/L精氨酸和6%甘油时,复性后人源溶菌酶的最佳比活力值为1170 U/mg,显著高于3种复性物均不加时溶菌酶335 U/mg的比活力值,但低于溶菌酶标准品1732 U/mg的比活力值。成功地将人源溶菌酶基因在大肠杆菌中表达,并通过包涵体复性体系成功获得高活性重组人源溶菌酶。     

ProNGF在大肠杆菌中的表达、纯化和复性

将含有前导肽的人神经生长因子基因(proNGF)克隆在原核表达载体pET15b中, 转化大肠杆菌BL21(DE3)pLysS, 经IPTG诱导实现了目标融合蛋白的高效表达。SDS-PAGE分析表明表达蛋白占全菌总蛋白的20%左右, 表达蛋白主要以包涵体的形式存在。用6 mol/L的盐酸胍溶解包涵体后, 通过Ni2+-NTA柱纯化, 获得纯化的目标融合蛋白, 电泳谱带扫描分析表明蛋白纯度可达90%以上。Western blotting检测显示, 表达产物有较强的免疫学活性。经肠激酶作用后得到proNGF非融合蛋白, 分子量为27 kD, 100 mL表达菌液可获得13.1 mg proNGF蛋白。用透析复性的方法将目的蛋白重折叠, 复性率为18%, 在重折叠过程中前导肽发挥了一定的积极作用。用PC12细胞进行生物活性鉴定, 结果显示复性后的proNGF蛋白具有良好的生物活性。     

ProNGF在大肠杆菌中的表达、纯化和复性

将含有前导肽的人神经生长因子基因(proNGF)克隆在原核表达载体pET15b中, 转化大肠杆菌BL21(DE3)pLysS, 经IPTG诱导实现了目标融合蛋白的高效表达。SDS-PAGE分析表明表达蛋白占全菌总蛋白的20%左右, 表达蛋白主要以包涵体的形式存在。用6 mol/L的盐酸胍溶解包涵体后, 通过Ni2+-NTA柱纯化, 获得纯化的目标融合蛋白, 电泳谱带扫描分析表明蛋白纯度可达90%以上。Western blotting检测显示, 表达产物有较强的免疫学活性。经肠激酶作用后得到proNGF非融合蛋白, 分子量为27 kD, 100 mL表达菌液可获得13.1 mg proNGF蛋白。用透析复性的方法将目的蛋白重折叠, 复性率为18%, 在重折叠过程中前导肽发挥了一定的积极作用。用PC12细胞进行生物活性鉴定, 结果显示复性后的proNGF蛋白具有良好的生物活性。     

Partial trisomy 21 (21q21 - 21q22.2)]

An abnormal chromosome 21 is reported in a child with a phenotype strongly reminiscent of trisomy 21 syndrome. It is shown to result from duplication of the segment 21q21 leads to 21q22.2. Comparison of the phenotype with that of other partial and total trisomics shows that the characteristic features of the trisomy 21 syndrome (mongolism), the mental retardation in particular - is due to trisomy 21q22.2 and perhaps 21q22.2.     

De novo 21/21 translocation Down syndrome

Summary Among ten families with de novo 21/21 translocation Down syndrome (tDS), four were informative, according to the studies of structural variants of chromosome 21, about the origin of the aberrant chromosome. In three of these, the translocation originated in the paternal and in one in the maternal gametogenesis. The parents with meiotic failure were compared with 20 control individuals (10 males and 10 females). There were no significant differences between them in the association coefficient of chromosome 21 and in the frequency of 21–21 associations. Similar results were obtained previously with the entire sample of tDS parents. The results obtained, unless they reflect too small a sample, suggest that the origin of the aberrant chromosome is not related to an increased chromosome 21 association tendency. It could be supposed that in the case of an apparent 21/21 translocation, the 21q isochromosome, morphologically indistinguishable from the Robertsonian translocation, is in question. The Ag-NoR negative acrocentrics in the tDS parents reappeared in the probands confirming the heritability of that nucleolus organizer regions (NOR) trait.     

Ring chromosome 21 in the mother and 21/21 translocation in the fetus: karyotype: 45,XX,-21,-21,+t(21;21)(p11;q11)

In 1984 we reported a ring chromosome 21 in a normal woman with recurrent fetal wastage (Kleczkowska and Fryns, 1984). A 46,XY normal fetal karyotype was found after prenatal diagnosis at 14 1/2 weeks in a third pregnancy of this woman. In the present paper we report the prenatal diagnosis of a 21/21 translocation in a female fetus from her fourth pregnancy.     

Isochromosome not translocation in trisomy 21q21q

Summary After primary trisomy, de novo 21q21q trisomy is the most frequent chromosomal aberration responsible for Down syndrome. This rearrangement is more commonly referred to as a Robertsonian translocation or centric fusion product than as an isochromosome, e.g., t(21q;21q) instead of i(21q); however, in practice, it has not so far proved possible to distinguish between these alternatives. The aim of this work was to establish which of the two alternatives is acceptable.     

CYP21 mutations in Brazilian patients with 21-hydroxylase deficiency

Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency is a common autosomal recessive disorder resulting from mutations in the 21-hydroxylase (CYP21) gene. To develop a strategy to screen for the most commonly occurring CYP21 mutations in Brazil, we performed molecular genotype analysis on 73 children with CAH representing 71 unrelated families. The techniques used for CYP21 molecular genotype analysis were: restriction fragment length polymorphism, single-strand conformational polymorphism, allele-specific oligonucleotide hybridization, allele-specific polymerase chain reaction amplification, and heteroduplex analyses. Mutations were identified on all but eight affected alleles. The intron 2 splicing mutation was the most frequently identified mutation. Screening for the most common mutations detected at least one mutation on 132/142 (93%) alleles. Multiple CYP21 mutations were detected on 16.2% of alleles. The high frequency of multiple mutations on a single allele emphasizes the importance of thorough and accurate molecular genotype analysis of the complex CYP21 locus.